Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Characteristics of included randomized controlled trials

From: Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Author

Year

Country

Study arms

Dose and frequency

Participants

Diabetes duration years

Age (y) Mean ± SD

Duration

BMI

Frías, J. P. [22]

2022

USA

Tirzepatide

5 mg/week

470

9.1 ± 7.16

56.3 ± 10.0

40 weeks

33.8 ± 6.85

10 mg/week

469

8.4 ± 5.90

57.2 ± 10.5

34.3 ± 6.6

15 mg/week

470

8.7 ± 6.85

55.9 ± 10.4

34.5 ± 7.11

Semaglutide

1 mg/week

469

8.3 ± 5.80

56.9 ± 10.8

34.2 ± 7.15

Vadher, K. [20]

2022

UK

Tirzepatide

5 mg/week

470

9.1 ± 7.2

56.3 ± 10.0

40 weeks

33.8 ± 6.9

10 mg/week

469

8.4 ± 5.9

57.2 ± 10.5

34.3 ± 6.6

15 mg/week

470

8.7 ± 6.9

55.9 ± 10.4

34.5 ± 7.1

Semaglutide

2 mg/week

480

8.3 ± 5.8

57.9 ± 10.0

34.2 ± 7.2

Ludvik, B. [16]

2021

Austria

Tirzepatide

5 mg/week

358

NP

57.2 ± 10.1

52 weeks

33.6 ± 5.9

10 mg/week

360

57.4 ± 9.7

33.4 ± 6.2

15 mg/week

358

57.5 ± 10.2

33.7 ± 6.1

Insulin degludec

10 U/day

359

57.5 ± 10.1

33.4 ± 6.1

Frias, J. P. [27]

2020

USA

Tirzepatide

5 mg/week

29

10.5 ± 7.90

61.2 ± 7.56

12 weeks

31.1 ± 4.21

10 mg/week

28

8.2 ± 4.87

55.5 ± 8.54

32.0 ± 5.56

15 mg/week

28

8.9 ± 6.35

56.6 ± 9.21

32.0 ± 5.19

Placebo

NP

26

8.8 ± 6.43

56.0 ± 10.13

32.5 ± 5.70

Dahl, D. [18]

2022

Germany

Tirzepatide

5 mg/week

116

14.1 ± 8.1

62 ± 10

40 weeks

33.6 ± 5.9

10 mg/week

119

12.6 ± 6.2

60 ± 10

33.4 ± 6.2

15 mg/week

120

13.7 ± 7.5

61 ± 10

33.4 ± 5.9

Insulin Glargine

 > 20 IU/day or > 0.25 IU/kg/d

120

12.9 ± 7.4

60 ± 10

33.2 ± 6.3

Wilson, J. M. [23]

2020

USA

Tirzepatide

5 mg/week

41

8.9 ± 5.7

57.9 ± 8.2

26 weeks

32.9 ± 5.7

10 mg/week

47

7.9 ± 5.8

56.5 ± 9.9

32.6 ± 5.8

15 mg/week

43

8.5 ± 6.1

56.0 ± 7.6

32.2 ± 6.2

Dulaglutide

1.5 mg/week

33

9.3 ± 7.1

58.7 ± 7.8

32.4 ± 5.4

Placebo

NP

41

8.6 ± 7.0

56.6 ± 8.9

32.4 ± 6.0

Furihata, K. [61]

2022

Japan

Tirzepatide

5 mg/week

11

7.0 ± 5.0

57.5 ± 7.9

8 weeks

26.7 ± 3.3

10 mg/week

12

8.4 ± 3.8

56.9 ± 9.5

25.5 ± 2.8

15 mg/week

16

9.1 ± 4.8

57.7 ± 8.0

26.1 ± 3.1

Placebo

NP

9

9.5 ± 3.4

57.4 ± 11.6

22.6 ± 2.1

Heise, T. [62]

2022

Germany

Tirzepatide

15 mg/week

45

10.24 ± 5.80

61.1 ± 7.1

28 weeks

NP

Semaglutide

1 mg/week

44

12.73 ± 6.10

63.7 ± 5.9

Placebo

NP

28

10.95 ± 6.78

60.4 ± 7.6

Inagaki, N. [63]

2022

Japan

Tirzepatide

5 mg/week

159

4.5 (2.1–7.5)

56.8 ± 10.1

52 weeks

28.6 ± 5.4

10 mg/week

158

5.1 (2.2–8.4)

56.2 ± 10.3

28.0 ± 4.1

15 mg/week

160

5.1 (2.2–8.4)

56.0 ± 10.7

28.1 ± 4.4

Dulaglutide

0.75 mg/week

159

5.0 (1.9–8.4)

57.5 ± 10.2

27.8 ± 3.7

Frias, J. P. [12]

2018

USA

Tirzepatide

5 mg/week

55

8.9 ± 5.7

57.9 ± 8.2

26 weeks

32.9 ± 5.7

10 mg/week

51

7.9 ± 5.8

56.5 ± 9.9

32.6 ± 5.8

15 mg/week

53

8.5 ± 6.1

56.0 ± 7.6

32.2 ± 6.2

Dulaglutide

1.5 mg/week

54

9.3 ± 7.1

58.7 ± 7.8

32.4 ± 5.4

Placebo

NP

51

8.6 ± 7.0

56.6 ± 8.9

32.4 ± 6.0

Rosenstock, J. [21]

2021

USA

Tirzepatide

5 mg/week

121

4.6 ± 5.1

54.1 ± 11.9

40 weeks

32.2 ± 7.0

10 mg/week

121

4.9 ± 5.6

55.8 ± 10.4

32.2 ± 7.6

15 mg/week

120

4.8 ± 5.0

52.9 ± 12.3

31.5 ± 5.5

Placebo

NP

113

4.5 ± 5.9

53.6 ± 12.8

31.7 ± 6.1

Del Prato, S. [17]

2021

USA

Tirzepatide

5 mg/week

329

9.8 (6.2–15.3)

62.9 ± 8.6

52 weeks

32.6 ± 6.06

10 mg/week

328

10.6 (6.5–16.2)

63.7 ± 8.7

32.8 ± 5.51

15 mg/week

338

10.4 (5.5–15.7)

63.7 ± 8.6

32.5 ± 5.02

Insulin Glargine

10 U/day

1000

10.7 (6.3–16.5)

63.8 ± 8.5

32.5 ± 5.55

Gao, L. [19]

2023

China

Tirzepatide

5 mg/week

230

7.43 ± 5.93

53.1 ± 11.2

40 weeks

28.1 ± 3.9

10 mg/week

228

7.9 ± 5.65

53.5 ± 11.1

27.7 ± 3.8

15 mg/week

229

7.64 ± 5.63

54.3 ± 11.6

27.8 ± 3.8

Insulin Glargine

 

220

7.65 ± 5.72

55.6 ± 11.4

28 ± 4.6

Garvey, W. T. [64]

2023

USA

Tirzepatide

5 mg/week

312

8.8 ± 6.9

54.3 ± 10.7

72 weeks

36.0 ± 6.4

15 mg/week

311

8.0 ± 6.4

53.6 ± 10.6

35.7 ± 6.1

Placebo

NP

315

8.8 ± 6.2

54.7 ± 10.5

36.6 ± 7.3

  1. NR not reported, USA United States of America, UK United Kingdom